Surgery Websites
Surgical Oncology Program »  Meet the Team »  Surgical Oncology »  Mohamed Abdelgadir Adam, M.D.
Mohamed Abdelgadir Adam, M.D.

Mohamed Abdelgadir Adam, M.D.

  • Assistant Professor of Surgery
  • Division of Surgical Oncology

Contact Information

Clinic Appointments:
UCSF Helen Diller Family Comprehensive Cancer Center
1825 Fourth Street, 4th Floor
San Francisco, CA 94158
Tel: 415-502-5577
Fax: 415-502-2236

Academic Office:
University of California, San Francisco
513 Parnassus Avenue, HSW 1601
San Francisco, CA 94143-0790
Tel: 415-514-3891
Fax: 415-476-8694
Open Popup

Education

MD: Faculty of Medicine and Health Sciences, Omdurman Islamic University, Sudan

Residencies

  • 2018: General Surgery Residency, Duke University Medical Center

Fellowships

  • 2020: Complex General Surgical Oncology Fellowship, University of Pittsburgh Medical Center, Pittsburgh, PA

Postdoctoral Training

  • 2010: Postdoctoral Research Fellowship, Duke Institute for Genome Sciences & Policy, Durham, NC
  • 2016: Research Fellowship, Duke Clinical Research Institute, Durham, NC

Board Certifications

  • American Board of Surgery, General Surgery

Clinical Expertise

Research Interests

  • Health Services Research
  • Leveraging translational artificial intelligence and machine learning in optimizing staging and management of gastrointestinal cancers.

Foreign Languages Spoken

  • Arabic

Biography

Mohamed Abdelgadir Adam is an assistant professor in the Division of Hepatobiliary and Pancreatic Surgery. He is a cancer surgeon who treats gastrointestinal tumors and specializes in the treatment of cancers of the pancreas and bile ducts. Dr. Adam has special expertise in robotic minimally invasive pancreato-biliary surgery, including robotic pancreaticoduodenectomy (Whipple procedure). Additionally, he has experience in regional treatment strategies for metastatic cancers in the liver and the peritoneal cavity, including placement of hepatic infusion pumps for patients with unresectable (colorectal and intrahepatic cholangiocarcinoma) liver disease and cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Dr. Adam received his medical degree from the Faculty of Medicine and Health Sciences. He completed general surgery training at Duke University Medical Center in Durham, NC. He continued his training with a two-year fellowship in complex surgical oncology at the University of Pittsburgh Medical Center in Pittsburgh, PA. Dr. Adam also completed two research fellowships at Duke University.

Dr. Adam's research focuses on leveraging translational artificial intelligence and machine learning algorithms to optimize cancer patients' treatment. He is a prolific researcher and has already authored over one hundred publications. He is a member of several professional societies. Dr. Adam already received many academic honors at Duke University and UCSF.

Research Overview

Dr. Adam's research focuses on leveraging translational artificial intelligence and machine learning algorithms to optimize cancer staging and treatment. He is a prolific researcher and has already authored over one hundred publications.

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 6
Data provided by UCSF Profiles, powered by CTSI
  1. Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM. Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Data-Driven, Machine Learning Approach to Augment Clinical Judgment. Ann Surg Oncol. 2023 Sep; 30(9):5433-5442. View in PubMed
  2. Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM. ASO Visual Abstract: Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy-A Data-Driven, Machine Learning Approach to Augment Clinical Judgement. Ann Surg Oncol. 2023 Sep; 30(9):5445-5446. View in PubMed
  3. Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH. ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Resection for Non-pancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2023 Jan; 30(1):177-178. View in PubMed
  4. Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2022 Aug 04. View in PubMed
  5. Adam MA, Glencer AC, Zureikat AH. ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2022 Jul 26. View in PubMed
  6. View All Publications

 

 
Site Directory
    X